Advanced search
Publication Cover
Leukemia & Lymphoma Volume 51, 2010 - Issue 3
Submit an article Journal homepage
67
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

Failure of molecular diagnostics in chronic myeloid leukemia: an aberrant form of e13a2 BCR–ABL transcript causing false-negative results by standard polymerase chain reaction

Tomáš JurčekCenter of Molecular Biology and Gene Therapy, Department of Internal Medicine–Hematooncology, University Hospital Brno and Masaryk University, Brno, Czech RepublicCorrespondence[email protected]
,
Filip RazgaCenter of Molecular Biology and Gene Therapy, Department of Internal Medicine–Hematooncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
,
Ivana JeziskovaCenter of Molecular Biology and Gene Therapy, Department of Internal Medicine–Hematooncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
,
Dana DvorakovaCenter of Molecular Biology and Gene Therapy, Department of Internal Medicine–Hematooncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
,
Daniela ZackovaDepartment of Internal Medicine–Hematooncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
,
Lenka TomasikovaDepartment of Medical Genetics, University Hospital Brno and Masaryk University, Brno, Czech Republic
,
Alexandra OltovaDepartment of Medical Genetics, University Hospital Brno and Masaryk University, Brno, Czech Republic
&
Jiri MayerDepartment of Internal Medicine–Hematooncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
 show all
Pages 558-561 | Received 07 Oct 2009, Accepted 17 Dec 2009, Published online: 12 Feb 2010

References

  • Melo JV, Myint H, Galton DA, Goldman JM. P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? Leukemia 1994;8:208–211.
  • Saglio G, Guerrasio A, Rosso C, et al New type of BCR-ABL junction in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1990;76:1819–1824.
  • Cross NC, Melo JV, Feng L, Goldman JM. An optimised multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in hematological disorders. Leukemia 1994;8:186–189.
  • Melo JV. BCR-ABL gene variants. Baillieres Clin Haematol 1997;10:203–222.
  • Leibundgut EO, Jotterand M, Rigamonti V. A novel BCR-ABL transcript e2a2 in a chronic myelogenous lekaemia patient with a duplicated Ph-chromosome and monosomy 7. Br J Haematol 1999;106:1041–1044.
  • Hochhaus A, Reiter A, Skladny H, et al A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia. Blood 1996;88:2236–2240.
  • Demehri S, Paschka P, Schultheis B, et al e8a2 BCR-ABL: more frequent than other atypical BCR-ABL variants? Leukemia 2005;19:681–684.
  • Branford S, Ruzki Z, Hughes TP. A novel BCR- ABL transcript (e8a2) with the insertion of an inverted sequence of ABL intron 1b in a patient with Philadelphia-positive chronic myeloid leukemia. Br J Haematol 2000;109:635–637.
  • Sugimoto T, Ijima K, Hisatomi H, et al Second case of CML with aberrant BCR-ABL fusion transcript (e8/a2) with insertion of an inverted ABL intron 1b sequence. Am J Hematol 2004;77:164–166.
  • Byrne JL, Carter GI, Davies JM, et al A novel BCR-ABL fusion gene (e2/a1) in a patient with Philadelphia-positive chronic myelogenous leukaemia and an aggresive clinical course. Br J Haematol 1998;103:791–794.
  • How GF, Lim LC, Kulkarni S, et al Two patients with novel BCR/ABL fusion transcripts (e8/a2 and e13/a2) resulting from translocation breakpoints within BCR exons. Br J Haematol 1999;105:434–436.
  • Burmeister T, Reinhardt R. A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts. Leuk Res 2008;32:579–585.
  • Lion T, Gaiger A, Henn T. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon. Leukemia 1995;9:1353–1360.
  • Lucas CM, Harris RJ, Giannoudis A, et al Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. Haematologica 2009;94:1362–1367.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.